Clinical trials in patients with acute kidney injury (AKI) have been stymied by a lack of consensus on suitable renal-specific end points. In a recent analysis, Grams et al. suggest that a sustained 30–40% reduction in estimated glomerular filtration rate after hospital discharge might be a suitable intermediate end point for AKI clinical trials.
References
Grams, M. E. et al. Candidate surrogate end points for ESRD after AKI. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2015070829 (2016).
International Society of Nephrology. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. 2, 1–138 (2012).
Coresh, J. et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311, 2518–2531 (2014).
Palevsky, P. M. et al. Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin. J. Am. Soc. Nephrol. 7, 844–850 (2012).
Okusa, M. D. et al. Design of clinical trials in acute kidney injury: a report from an NIDDK workshop — prevention trials. Clin. J. Am. Soc. Nephrol. 7, 851–855 (2012).
Molitoris, B. A. et al. Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings. Clin. J. Am. Soc. Nephrol. 7, 856–860 (2012).
Go, A. S. et al. The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. BMC Nephrol. 11, 22 (2010).
Weisbord, S. D. et al. Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin. J. Am. Soc. Nephrol. 8, 1618–1631 (2013).
Matthay, M. A. & Liu, K. D. New strategies for effective therapeutics in critically ill patients. JAMA 315, 747–748 (2016).
Liu, K. D. & Glidden, D. V. Clinical trials for acute kidney injury: design challenges and possible solutions. Curr. Drug Targets 10, 1190–1195 (2009).
Acknowledgements
K.D.L. has received funding from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (grant number 5R01DK098233) and from the National Heart, Lung, and Blood Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.D.L. has consulted for ZS Pharma, Achaogen, Chemocentryx, and Durect. She has received compensation for travel from the American Society of Nephrology. She is an Amgen stockholder. M.P. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Parks, M., Liu, K. Clinical trials in AKI: is the end in sight?. Nat Rev Nephrol 12, 263–264 (2016). https://doi.org/10.1038/nrneph.2016.35
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.35
- Springer Nature Limited